Kallidinogenase clinical trials
How each study uses kallidinogenase is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the kallidinogenase studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Human Urinary Kallidinogenase
- 4
Studies by the year they started
4 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2023 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 4
XuanwuH 2 (1) · China-Japan Union Hospital (1) · Beijing Tsinghua Chang Gung Hospital (1) · General Hospital of Shenyang Military Region (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test kallidinogenase.
- Sep 2027Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS)Phase 2 · General Hospital of Shenyang Military Region
Studies
Open first, then newest update. How each study uses kallidinogenase is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic StrokeNot yet recruitingNot applicableChina-Japan Union HospitalNCT07483281Written as Human Urinary Kallidinogenase
- Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS)RecruitingPhase 2General Hospital of Shenyang Military RegionNCT07283159Written as Human Urinary Kallidinogenase
- Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED)Not yet recruitingNot applicableBeijing Tsinghua Chang Gung HospitalNCT06132880Written as Human Urinary Kallidinogenase
- Multi-modality MRI Study on Effect to Collateral Circulation and Blood Perfusion of Acute Cerebral Infarction by Human Urinary KallidinogenaseCompletedPhase 2XuanwuH 2NCT02259738Written as Human Urinary Kallidinogenase
As the comparator · 1 — what is tested is compared with kallidinogenase
Codes
What other systems call kallidinogenase · ClinicalTrials.gg INT035256
- UNII (FDA) OT9M1PSK9NKALLIDINOGENASEOne source FDA
- NCI Thesaurus C174812KallidinogenaseOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | OT9M1PSK9N | KALLIDINOGENASE | One source FDA |
| NCI Thesaurus | C174812 | Kallidinogenase | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.